FDA Approves Biogen Alzheimer’s Drug

FDA Approves Biogen Alzheimer’s Drug
A researcher works on the development of the medication aducanumab in Cambridge, Mass., in 2019. Biogen via AP
Reuters
Updated:

Government health officials on Monday approved Biogen’s aducanumab as the first treatment to attack a likely cause of Alzheimer’s disease, sending its shares soaring, despite controversy over whether the clinical evidence proves the drug works.

Biogen said it has priced the drug, to be sold as Aduhelm, at $56,000 per year. Its shares jumped nearly 52 percent to $434.52 when trading resumed following the approval. U.S. traded shares of partner Eisai Co were already up $33.50, or 45 percent, to $107.75